DESTINATION 2 Trial
The central hypothesis is that de-escalated two-fraction prostate SBRT will reduce acute grade 2 or higher genitourinary adverse events compared with uniform-dose two-fraction SBRT. Both treatment arms are experimental because optimal MRI-…
1 sources - 5 claims
The central hypothesis is that de-escalated two-fraction prostate SBRT will reduce acute grade 2 or higher genitourinary adverse events compared with uniform-dose two-fraction SBRT. Both treatment arms are experimental because optimal MRI-guided two-fraction SBRT regimens are not established. The trial tests whether de-escalating dose to benign-appearing prostate tissue while maintaining tumoricidal dose to visible tumor can reduce genitourinary adverse events without compromising disease control.